Your session is about to expire
← Back to Search
Enzyme
Drug: ADI-PEG 20 plus Pem Platinum for Mesothelioma (ATOMIC Trial)
Phase 2 & 3
Waitlist Available
Research Sponsored by Polaris Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically proven unresectable MPM of biphasic or sarcomatoid histology
Naïve to chemotherapy or immunotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
ATOMIC Trial Summary
This trial is testing whether a drug that breaks down arginine can help treat people with mesothelioma.
Eligible Conditions
- Mesothelioma
ATOMIC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowATOMIC Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall Survival
Overall Survival Phase 3 Interim Analysis
Response Rate
Secondary outcome measures
Progression Free Survival
Side effects data
From 2022 Phase 2 & 3 trial • 249 Patients • NCT0270951253%
Fatigue
52%
Nausea
43%
Constipation
27%
Anemia
21%
Decreased Appetite
5%
Acute Kidney Injury
5%
Dyspnoea
4%
Pneumonia
4%
Pyrexia
3%
Atrial Fibrillation
2%
Fall
2%
Anaphylactic Reaction
1%
Musculoskeletal Testing
1%
Cerebrovascular Accident
1%
Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Drug: Placebo Plus Pem Platinum
Drug: ADI-PEG 20 Plus Pem Platinum
ATOMIC Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug: ADI-PEG 20 plus Pem PlatinumExperimental Treatment1 Intervention
Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study
In Combination With:
Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous
ADI-PEG 20 plus Pem Platinum: Investigational Drug in combination approved standard of care treatment for this indication
Group II: Drug: Placebo plus Pem PlatinumPlacebo Group1 Intervention
Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study
In Combination With:
Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Carboplatin Dose: AUC 5 mg/mL/min every 3 weeks Route of Administration: Intravenous
Placebo plus Pem Platinum: Placebo in combination approved standard of care treatment for this indication
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADI-PEG 20 plus Pem Platinum
2017
Completed Phase 3
~250
Find a Location
Who is running the clinical trial?
Polaris GroupLead Sponsor
24 Previous Clinical Trials
3,038 Total Patients Enrolled
1 Trials studying Mesothelioma
85 Patients Enrolled for Mesothelioma
John S Bomalaski, MDStudy DirectorPolaris Group
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger